Pelvic organ collapse is very common, with around half of women experiencing it to some degree in their lifetime. Image credit: Shutterstock/Syda Productions.

The US Food and Drug Administration (FDA) has granted clearance to Cosm Medical for its Gynethotics Pessaries for pelvic floor disorders.

The current gold standard to fit a pessary involves taking manual finger measurements. Cosm uses artificial intelligence (AI) and 3D printing to create patient-specific pessaries. The pessaries are made of silicone with varying choices of material stiffness.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Cosm states that unlike current options available, which have around 100 configurations, its product comes in almost ten million shapes and provides patients with a level of personalisation.

The clearance, which comes hot on the heels of an approval by Health Canada, follows results from Cosm’s pilot study at Sinai Health Systems in Toronto, Canada.

Cosm, which is based in Toronto, published the data from the study in Urogynecology in 2023. The results showed that changing from a standard pessary to patient-specific pessary treatment improved prolapse symptoms and overall pessary satisfaction.

See Also:

Vaginal pessaries are an effective treatment for patients with pelvic organ prolapse. The removable devices, which are usually made of latex or silicone, provide a non-surgical option. However, patients sometimes struggle to find a good fit. NHS England tells patients with pelvic organ prolapse that different types and sizes may need to be tried. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pelvic organ collapse is very common, with around half of women experiencing it to some degree in their lifetime. More than 12% of US women have surgery for the condition.

Cosm’s CEO Derek Sham said: “Our vision is to become the world leader in precision gynaecological devices for unique bodies and needs. With our first FDA clearance, we are one step closer to realising this vision and making a meaningful impact on the lives of over a million patients by 2030.”

The clearance adds to the increasing innovation seen in the femtech space, as the market gains more investment and awareness. Despite the generally weaker investment landscape dominating life sciences, femtech is seeing one of the fastest compound annual growths in the industry.